See more : TIER 1 Technology, S.A. (TR1.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Outset Medical, Inc. (OM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Outset Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Doosan Robotics Inc. (454910.KS) Income Statement Analysis – Financial Results
- Prysmian S.p.A. (PRYMY) Income Statement Analysis – Financial Results
- Hangzhou Jizhi Mechatronic Co., Ltd. (300553.SZ) Income Statement Analysis – Financial Results
- MFC Asset Management Public Company Limited (MFC.BK) Income Statement Analysis – Financial Results
- Lavvi Empreendimentos Imobiliários S.A. (LAVV3.SA) Income Statement Analysis – Financial Results
Outset Medical, Inc. (OM)
About Outset Medical, Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 130.38M | 115.38M | 102.60M | 49.94M | 15.08M | 2.01M |
| Cost of Revenue | 101.38M | 97.54M | 94.99M | 62.97M | 32.88M | 8.12M |
| Gross Profit | 29.00M | 17.83M | 7.61M | -13.04M | -17.80M | -6.12M |
| Gross Profit Ratio | 22.24% | 15.46% | 7.42% | -26.11% | -118.07% | -304.68% |
| Research & Development | 57.31M | 48.86M | 36.74M | 28.85M | 23.33M | 22.92M |
| General & Administrative | 45.23M | 40.52M | 36.32M | 30.51M | 8.92M | 6.25M |
| Selling & Marketing | 96.23M | 89.48M | 65.07M | 45.07M | 20.26M | 11.28M |
| SG&A | 141.46M | 130.00M | 101.39M | 75.58M | 29.18M | 17.53M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 198.77M | 178.85M | 138.13M | 104.43M | 52.51M | 40.45M |
| Cost & Expenses | 300.15M | 276.39M | 233.12M | 167.40M | 85.39M | 48.57M |
| Interest Income | 10.17M | 3.29M | 498.00K | 526.00K | 2.49M | 1.71M |
| Interest Expense | 12.68M | 3.57M | 1.72M | 2.37M | 4.26M | 4.64M |
| Depreciation & Amortization | 5.81M | 6.28M | 6.18M | 3.76M | 1.94M | 1.49M |
| EBITDA | -153.79M | -152.81M | -124.86M | -114.85M | -62.09M | -43.62M |
| EBITDA Ratio | -117.96% | -136.71% | -126.72% | -235.24% | -436.97% | -2,181.61% |
| Operating Income | -169.77M | -161.02M | -130.52M | -117.47M | -70.31M | -46.56M |
| Operating Income Ratio | -130.22% | -139.56% | -127.21% | -235.24% | -466.29% | -2,320.03% |
| Total Other Income/Expenses | -2.50M | -1.64M | -1.22M | -4.03M | 2.03M | -3.19M |
| Income Before Tax | -172.27M | -162.66M | -131.74M | -121.49M | -68.28M | -49.76M |
| Income Before Tax Ratio | -132.14% | -140.98% | -128.40% | -243.30% | -452.84% | -2,479.07% |
| Income Tax Expense | 523.00K | 295.00K | 199.00K | -794.00K | 20.00K | 25.00K |
| Net Income | -172.80M | -162.96M | -131.94M | -120.70M | -68.30M | -49.78M |
| Net Income Ratio | -132.54% | -141.24% | -128.59% | -241.71% | -452.97% | -2,480.32% |
| EPS | -3.48 | -3.38 | -2.89 | -2.83 | -1.61 | -1.65 |
| EPS Diluted | -3.48 | -3.38 | -2.89 | -2.83 | -1.61 | -1.65 |
| Weighted Avg Shares Out | 49.59M | 48.16M | 45.59M | 42.72M | 42.33M | 30.08M |
| Weighted Avg Shares Out (Dil) | 49.59M | 48.16M | 45.59M | 42.72M | 42.33M | 30.08M |
Outset Medical (OM) Shares Down 94% Since Disclosing FDA Warning Letter, Morgan Stanley And JPMorgan Chase Unload Most Of Their Positions In OM Shares - Hagens Berman
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ: OM) is facing a perilous situation as it grapples with a potential delisting from the Nasdaq and a class-action lawsuit alleging investor fraud. In a notice received on...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Outset Medical, Inc. (OM) Shareholders
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Investors in Outset Medical, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – OM
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM).
Levi & Korsinsky Reminds Outset Medical Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - OM
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Outset Medical Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b)...
Class Action Filed Against Outset Medical, Inc. (OM) - October 28, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company")...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Outset Medical, Inc. Lawsuit – OM
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
October 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against OM
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Outset Medical, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – OM
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the...
Source: https://incomestatements.info
Category: Stock Reports